Primary central nervous system lymphomas (PCNSL): MRI response criteria revised

Neurology

Volumn 65, Issue 7, 2005, Pages 1129-1131

  Küker, Wilhelm ^a,c   Nagele T ^a   Thiel, E ^b   Weller, M ^a   Herrlinger, U ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CONTRAST ENHANCEMENT; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 26444512661     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000178894.51436.54     Document Type: Article

References (6)

1. Roman Goldstein SM, Goldman DL, Howieson J, Belkin R, Neuwelt EA. MR of primary CNS lymphoma in immunologically normal patients. AJNR Am J Neuroradiol 1992;13:1207-1213.
2. Lanfermann H, Heindel W, Schaper J, et al. CT and MR imaging in primary cerebral non-Hodgkin's lymphoma. Acta Radiol 1997;38:259-267.
3. Bühring U, Herrlinger U, Krings T, et al. MRI features of primary central nervous system lymphomas (PCNSL) at presentation. Neurology 2001;57:393-396.
4. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
5. Herrlinger U, Schabet M, Brugger W, et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 2002;51:247-252.
6. Kuker W, Nagele T, Korfel A, et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 2005;72:169-177.